The global inhaled biologics market size was valued at USD 3.72 billion in 2025 and is projected to grow from USD 4.23 billion in 2026 to USD 11.81 billion by 2034, registering a CAGR of 13.71% during the forecast period (2026–2034). North America dominated the inhaled biologics market with a market share of 38.62% in 2025.
Inhaled biologics are advanced therapeutic systems designed to deliver biologic drugs directly to the respiratory tract through inhalation technologies. These therapies enable targeted treatment of chronic respiratory conditions such as asthma, chronic obstructive pulmonary disease, and pulmonary infections by improving drug delivery efficiency and reducing systemic side effects.
The inhaled biologics market demand is driven by the rising prevalence of respiratory disorders, growing adoption of targeted therapies, and advancements in inhalation drug delivery technologies. Increasing research investments, expanding biologics development, and supportive healthcare infrastructure are also contributing to inhaled biologics market growth.
Download a Free Sample To learn more about this report,
Rising Adoption of Smart Inhalation Platforms for Biologic Drug Delivery
The inhaled biologics market is witnessing a shift toward smart inhalation platforms that combine biologic therapies with digital monitoring technologies. These systems help track inhaler usage, optimize dosing accuracy, and improve patient adherence in chronic respiratory disease management. For example, connected inhaler technologies developed by companies such as AstraZeneca are supporting digitally enabled respiratory care approaches by integrating treatment monitoring with patient management solutions.
Growing Development of Targeted Pulmonary Delivery Technologies for Complex Biologics
A major trend in the inhaled biologics market is the advancement of specialized delivery technologies that improve lung deposition of complex biologic molecules. Challenges related to molecule stability and absorption are driving innovation in aerosol formulations and device platforms. For example, Insmed Incorporated received FDA approval for Arikayce (amikacin liposome inhalation suspension), the first inhaled liposomal antibiotic approved for Mycobacterium avium complex lung disease, demonstrating the potential of advanced inhalation systems to deliver complex therapies directly to the lungs while reducing systemic exposure.
The inhaled biologics market forecasts continued investment activity driven by increasing focus on targeted respiratory therapies, rising prevalence of chronic lung diseases, and advancements in inhalation biologic delivery platforms.
Key Investment and Funding Activities in Inhaled Biologics Market, 2025–2026
Kinaset Therapeutics
USD 103 million (Series B financing)
In January 2026, Kinaset raised Series B funding to progress frevecitinib, an inhaled pan-JAK inhibitor, through Phase 2 studies for severe asthma.
Avalyn Pharma Inc.
USD 100 million (Series D financing)
In July 2025, Avalyn completed an oversubscribed Series D round to advance clinical development of inhaled therapies targeting pulmonary fibrosis and other severe pulmonary diseases.
Source: Secondary Research
The inhaled biologics market is sensitive to disruptions due to its dependence on specialized biologic manufacturing, complex supply networks, cold-chain logistics, and availability of advanced inhalation delivery components. Supply chain disruptions have reshaped the market ecosystem by creating challenges in raw material procurement, clinical trial timelines, production scalability, and global distribution of biologic therapies. These disruptions have affected the industry worldwide by increasing manufacturing costs, causing delays in product launches, and influencing healthcare providers’ access to innovative respiratory treatments. The market is expected to follow an S-shaped recovery, with gradual stabilization driven by improved supply chain resilience, expanded manufacturing capabilities, diversified sourcing strategies, and increasing adoption of advanced inhaled biologic therapies.
Rising Prevalence of Chronic Respiratory Diseases and Increasing Focus on Needle-Free Administration Drive Market
The increasing burden of asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and other respiratory disorders is driving demand for advanced inhaled biologic treatments. The growing patient population with uncontrolled respiratory conditions is encouraging pharmaceutical companies to develop therapies that provide localized action in the lungs with improved efficacy and reduced systemic effects. For example, AstraZeneca and Amgen are advancing tezepelumab delivery research for severe asthma, building on the success of Tezspire, an anti-TSLP biologic approved for severe asthma management. These developments highlight increasing interest in biologics targeting inflammatory pathways involved in respiratory diseases and support market expansion.
The growing preference for non-invasive and patient-friendly drug administration methods is driving demand for inhaled biologic therapies as an alternative to conventional injectable biologics. Patients with chronic respiratory conditions often require long-term treatments, creating the need for convenient delivery options that improve adherence and reduce treatment burden. For example, Boehringer Ingelheim is developing inhaled biologic approaches, including pulmonary delivery technologies for respiratory diseases, to explore more convenient administration routes for complex therapies.
Limited Reimbursement Coverage and High Treatment Costs Restrain Market Expansion
Limited reimbursement support for newer inhaled biologic therapies reduces financial incentives for healthcare providers to adopt these treatments, particularly in cost-sensitive markets. Payers often require strong clinical and economic evidence before including innovative biologic therapies in coverage programs. Thus, inconsistent reimbursement policies restrain market growth by affecting treatment affordability and reducing patient access to advanced inhaled biologic solutions.
Inhaled biologics generally involve higher pricing compared with traditional inhaled corticosteroids, bronchodilators, and other established respiratory treatments due to their complex development and manufacturing processes. This cost difference influences prescribing decisions and limits adoption among price-sensitive patient populations. Thus, the premium cost of inhaled biologic therapies remains a significant restraint affecting market penetration and volume growth.
Development of Inhaled Gene and RNA-Based Therapies and Increasing Adoption of Home-Based Respiratory Care Offer Growth Opportunities to Market Players
The growing development of inhaled gene and RNA-based medicines creates a significant growth opportunity for biotechnology companies developing next-generation respiratory therapies. Direct pulmonary delivery can enable targeted treatment of genetic and inflammatory lung disorders while reducing systemic exposure. Companies such as Arcturus Therapeutics are exploring inhaled RNA delivery approaches for respiratory applications. Future adoption of inhaled nucleic acid therapies can expand the role of inhaled biologics beyond conventional protein-based treatments and create new therapeutics.
The shift toward home-based management of chronic respiratory diseases creates growth opportunities for companies developing convenient inhaled biologic delivery systems. Patient-friendly inhalation technologies can support long-term therapy administration outside hospital settings while improving treatment adherence. Future integration of portable delivery devices and digital monitoring solutions can accelerate adoption of inhaled biologics in outpatient and home-care environments.
Complex Manufacturing Requirements and Need to Maintain Drug Stability and Efficient Pulmonary Delivery Challenge Market Growth
The complex development and manufacturing processes for inhaled biologics require advanced formulation techniques, specialized equipment, and strict quality control to maintain biologic stability and delivery efficiency. These factors increase production costs and create challenges in scaling commercial manufacturing. Thus, high manufacturing complexity and cost requirements act as restraints by limiting accessibility and slowing broader adoption of inhaled biologic therapies.
Biologic molecules are sensitive to environmental conditions and can experience stability issues during formulation, aerosolization, and storage processes. These limitations may impact drug potency, lung deposition efficiency, and therapeutic performance, requiring additional investments in research and development.
The peptides & proteins segment accounted for a share of 31.27% in 2025 due to established clinical pipelines, proven therapeutic activity in pulmonary disorders, and compatibility with existing nebulization technologies. Their relatively advanced development stage enabled faster clinical translation and greater pharmaceutical investment.
The RNAi-based therapeutics segment is expected to grow at a CAGR of around 14.68% during the forecast period due to increasing development of inhaled gene silencing therapies, improvements in pulmonary nanoparticle delivery, and expanding research targeting rare genetic lung diseases.
Request Customizationto receive a tailored report.
The respiratory diseases segment accounted for a share of 66.87% in 2025 due to direct pulmonary drug administration, high unmet need in severe chronic respiratory disorders, and increasing biologic development targeting localized airway inflammation.
The diabetes segment is expected to grow at a CAGR of 14.85% during the forecast period, driven by renewed investment in inhaled insulin technologies, increasing preference for needle-free therapies, and expansion of pediatric inhaled insulin indications.
The hospital pharmacies segment accounted for a share of 47.19% in 2025 due to centralized dispensing of specialty biologics, physician-supervised treatment initiation, and cold-chain handling requirements for advanced inhaled therapies.
The retail pharmacies segment is expected to grow at a CAGR of 15.07% during the forecast period, driven by increasing availability of specialty pharmacy services, expansion of outpatient respiratory care, and growing dispensing of chronic maintenance therapies.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Strong Biopharmaceutical Innovation and High Adoption of Advanced Respiratory Therapies
The North America inhaled biologics market accounted for the largest regional share of 38.62% in 2025, driven by a strong biopharmaceutical innovation ecosystem, increasing adoption of advanced biologic therapies for respiratory diseases, and robust clinical research activity. The region benefits from the presence of leading biotechnology companies, favorable regulatory pathways, and extensive specialty respiratory care infrastructure.
The US inhaled biologics market was valued at USD 1.25 billion in 2025, driven by high prevalence of severe asthma, COPD, cystic fibrosis, and other chronic respiratory disorders requiring advanced targeted therapies. The country's well-established biotechnology sector, specialized pulmonary care centers, and strong regulatory support for innovative therapies are accelerating commercialization of inhaled biologic products. According to the Centers for Disease Control and Prevention (CDC), nearly 28 million people in the US have asthma, including about 4.5 million children, creating sustained demand for innovative biologic and inhalation-based respiratory therapies.
The inhaled biologics market in Canada was valued at USD 185.49 million in 2025, supported by increasing investment in respiratory disease research, expanding access to specialty biologic therapies, and growing focus on personalized pulmonary care. Canadian healthcare institutions are actively participating in clinical studies evaluating innovative inhaled biologic platforms for chronic respiratory diseases.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Driven by Expanding Respiratory Biopharmaceutical Manufacturing and Rising Clinical Development of Inhaled Therapies
The Asia Pacific inhaled biologics market is expected to grow at a CAGR of 15.83% during the forecast period, showcasing the fastest regional growth. The region is also benefiting from increasing respiratory disease burden and growing investments in advanced pulmonary drug delivery technologies. According to ClinicalTrials.gov, Asia Pacific countries, particularly China, Japan, and South Korea, have witnessed a steady increase in respiratory biologic clinical trials, reflecting the region's expanding innovation ecosystem.
The China inhaled biologics market was valued at USD 178.26 million in 2025, supported by rapid expansion of domestic biologics manufacturing, government initiatives promoting innovative drug development, and increasing investment in inhalation drug delivery platforms. The country's "Healthy China 2030" strategy and regulatory reforms are accelerating approval pathways for innovative biologics.
The India inhaled biologics market was valued at USD 91.18 million in 2025, fueled by expanding contract development and manufacturing (CDMO) capabilities for biologics, increasing respiratory disease burden, and rising investments in biosimilar and novel biologic research. Government initiatives supporting biotechnology innovation and the growing presence of respiratory specialty hospitals are encouraging development of affordable inhaled biologic therapies.
The Japan inhaled biologics market was valued at USD 105.20 million in 2025, supported by strong expertise in respiratory medicine, high adoption of precision therapeutics, and increasing research focused on advanced pulmonary drug delivery systems. Japan's aging population and high prevalence of chronic respiratory diseases are encouraging the development of innovative biologic therapies with improved safety and convenience. The country's well-established regulatory framework for regenerative medicine and biologics continues to accelerate innovation in inhaled respiratory treatments.
The inhaled biologics market competitive landscape is evolving, with competition concentrated among pharmaceutical and biotechnology companies developing advanced respiratory biologics, pulmonary delivery platforms, and targeted therapeutic solutions. Leading players compete through innovation in biologic formulations, inhalation technologies, clinical development capabilities, and strategic collaborations to strengthen their market position. Emerging companies focus on novel delivery approaches, RNA-based therapies, and specialized respiratory treatments. The inhaled biologics market ecosystem is shaped by increasing demand for targeted lung therapies, advancements in drug delivery technologies, regulatory developments, and the need for effective treatments with improved patient outcomes.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Breast Cancer Liquid Biopsy Market Size, Share, Growth, Analysis, 2034
Cell-free DNA Testing Market Size, Share, Growth, 2034
Non-invasive Cancer Diagnostics Market Size, Share, Growth, 2034
RNA Therapeutics Market Size, Share, Growth, Forecast, 2034
Mitochondrial DNA (mtDNA) Market Size, Share, Growth, Analysis, 2034
Biopharmaceutical Fermentation Systems Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com